Express Press Release Distribution

Accounting
Advertising
Aerospace
Agriculture
Apparel & Fashion
Automotive
Biotech
Chemicals
Computers
Construction
Consumer Services
Defense
Education
Electronics
Energy
Entertainment
Environment
Financial
Food & Beverage
Government
Healthcare
Human Resources
Industrial
International Trade
Internet & Online
Law
Management
Marketing
Media
Non Profit
Pharmaceuticals
Real Estate
Retail
Semiconductors
Small Business
Software
Sports
Telecommunications
Transportation / Logistics
Travel

EPR Archived News

Archived News 2012
~ April
~ March
~ February
~ January

Archived News 2011
~ December
~ November
~ October
~ September
~ August
~ July
~ June
~ May
~ April
~ March
~ February
~ January

Archived News 2010
Archived News 2009
Archived News 2008
Archived News 2007
Archived News 2006
Archived News 2005
Archived News 2004

 

MD Biosciences and Becton Dickinson sign Agreement For the Distribution of Streptococcus Cell Wall Extract, PG-PS.

Released on = April 7, 2005, 9:07 pm

Press Release Author = Amy Clausen

Industry = Biotech

Press Release Summary = MD Biosciences announces today that it has entered into an agreement with BD Lee Laboratories to sell PG-PS (peptidoglycan-polysaccharide polymer streptococcus cell wall extract) products for induction of inflammatory response in in vivo models of disease.

Press Release Body = St. Paul, MN, April 08, 2005 – MD Biosciences, an international provider of inflammatory research products and pre-clinical services, announces today that it has entered into an agreement with BD (Becton Dickinson and Company) Lee Laboratories to sell PG-PS (peptidoglycan-polysaccharide polymer streptococcus cell wall extract) products. BD Lee Laboratories approached MD Biosciences for its established leadership in inflammations research and the agreement will serve to expand and strengthen MD Biosciences inflammatory research product line.

PG-PS is purified polymers produced from the cell walls of Streptococcus pyogenes Group A. The use of these polymers in in vivo models of disease induces an acute and chronic inflammatory reaction, which can evolve into a remittent, arthritic response that is representative of naturally caused inflammatory disorders. “The addition of PG-PS will complement our focused product line of inflammatory research reagents and will provide an additional resource for clients who are engaged in in vivo models of disease for their drug discovery efforts” commented Amy Clausen, Marketing Manager for MD Biosciences.

PG-PS is a valuable resource to researchers involved in inflammatory drug discovery. The induction of a biphasic inflammatory response in disease models is used for the evaluations and studies of anti-inflammatory drugs and therapies for inflammatory diseases such as arthritis, granulomatous enterocolitis (resembling Crohn’s disease), and others.

About MD Biosciences
MD Biosciences (www.mdbiosciences.com) is an international biotech company providing the most advanced products and pre-clinical services for pharmaceutical and biotechnology companies engaged in inflammations research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally
recognized experts provides in-depth expertise and technologies to tackle problems and provide total solutions to the inflammatory disease drug discovery market.

About BD Lee Laboratories
Lee Laboratories, a fully owned subsidiary of BD (Becton Dickinson), offers reagents and services for diagnostics and inflammation research. BD is a medical technology company that serves life science researchers, clinical laboratories, and the healthcare industry.

--------

The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Web Site = http://www.mdbiosciences.com

Contact Details = MD Biosciences
1000 Westgate Dr
St Paul, MN 55114
651-641-1770
651-641-1773 (fax)
info-us@mdbiosciences.com


  • Printer Friendly Format
  • Back to previous page...
  • Back to home page...
  • Submit your press releases...
  •